Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Dec. 2025,
S2Medical AB receivedkr1.25 Mil more from issuing new shares than it paid to buy back shares.
It receivedkr0.00 Mil from issuing more debt.
It paidkr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedkr0.00 Mil from paying cash dividends to shareholders.
It receivedkr0.00 Mil on other financial activities.
In all, S2Medical ABearnedkr1.25 Mil on financial activities for the
six
months ended in Dec. 2025.
S2Medical AB (OSTO:S2M) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
S2Medical AB's issuance of stock for the
six
months ended in Dec. 2025 was kr1.25 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
S2Medical AB's repurchase of stock for the
six
months ended in Dec. 2025 was kr0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
S2Medical AB's net issuance of debt for the
six
months ended in Dec. 2025 was kr0.00 Mil.
S2Medical AB receivedkr0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
S2Medical AB's net issuance of preferred for the
six
months ended in Dec. 2025 was kr0.00 Mil.
S2Medical AB paidkr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
S2Medical AB's cash flow for dividends for the
six
months ended in Dec. 2025 was kr0.00 Mil.
S2Medical AB receivedkr0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
S2Medical AB's other financing for the
six
months ended in Dec. 2025 was kr0.00 Mil.
S2Medical AB receivedkr0.00 Mil on other financial activities.
S2Medical AB Cash Flow from Financing Related Terms
S2Medical AB Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for S2Medical AB's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
S2Medical AB's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr1.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of kr1.25 Mil mean?
S2Medical AB (OSTO:S2M) has a Cash Flow from Financing of kr1.25 Mil as of Dec. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for S2Medical AB and its competitors.
Is S2Medical AB's Cash Flow from Financing too high?
S2Medical AB's current Cash Flow from Financing is kr1.25 Mil.
How does S2Medical AB's Cash Flow from Financing compare to ISRG and BDX?
S2Medical AB's Cash Flow from Financing of kr1.25 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Medical Devices & Instruments company?
A good Cash Flow from Financing depends on the Medical Devices & Instruments industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for S2Medical AB and its competitors. S2Medical AB's current Cash Flow from Financing is kr1.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is S2Medical AB stock overvalued right now?
Based on GuruFocus' analysis, S2Medical AB (OSTO:S2M) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.01, compared to a current price of kr0.01 — trading 38% below its estimated fair value. The current Cash Flow from Financing is kr1.25 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For S2Medical AB (OSTO:S2M), the current Cash Flow from Financing is kr1.25 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
S2Medical AB is a research-intensive MedTech company from Sweden. The company develops products within the entire wound healing process from debridement and granulation to re-epithelialization. products for the initial phase of a wound's healing process until the end, when the wound is completely healed. S2Medical also has in its portfolio the product NoSmell for odor removal which is procured in several different Swedish healthcare regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:S2M has been successfully added to your 
